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Multiple myeloma is an incurable malignant disorder of mature B-cells that predominantly affects the elderly. The
immunomodulatory drug (IMiD) thalidomide and its newer analogs demonstrate increased antitumor activity, and
have had a positive impact on the natural history of multiple myeloma. Recent advances in the clinical application
of these agents and in our understanding of their mechanism of action, and toxicity have made safer and smarter
use of these drugs possible. This review discusses the available information regarding mechanisms of action,
toxicity and clinical results on thalidomide, lenalidomide and pomalidomide in the therapy of multiple myeloma.
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Multiple myeloma is a mature B-cell neoplasm charac-
terized by a monoclonal expansion of plasma cells in the
bone marrow often accompanied by hemocytopenias,
immunodeficiency, osteolytic lesions, hypercalcemia and
renal failure. Myeloma accounts for about 10% of all
hematological malignancies and 1% of all cancers [1].
In United States alone an estimated 20,520 new cases
(11,400 men and 9120 women) will be diagnosed
in 2011 and 10,610 people will die of myeloma [2].
Ever since the first reported case of ‘mollities ossium’
described in 1844 [3], the disease has remained incur-
able, despite a better understanding of its pathogenesis
and recent advancements in therapeutics. Prior to the
advent of alkylating agents, the median survival for mul-
tiple myeloma was 1–1.5 years [4]. Following the intro-
duction of L-phenylalanine mustard or melphalan in
1958 [5] and prednisone in 1962 [6], the combination of
these two drugs remained the cornerstone of therapy for
more than two decades, even though the complete re-
mission rate remained less than 5% and the median sur-
vival with this treatment did not exceed 3 years [7].
Since the late 1990s, a number of new classes of drugs
have been incorporated in the treatment of multiple
myeloma and additional agents are under investigation* Correspondence: susmani@uams.edu
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reproduction in any medium, provided the or(Figure 1). The present paper will review the clinical
data for the use of thalidomide and its analogs, collect-
ively referred as immunomodulatory drugs or IMiDs in
multiple myeloma.The history and toxicity of immunomodulatory drugs
(IMiDs)
Thalidomide was first introduced as an oral sedative and
anti-emetic in 1957, but was quickly abandoned due to
its profound teratogenic effects. Almost four decades
passed before studies demonstrated thalidomide to have
anti-cancer properties, specifically showing significant
in vitro anti-myeloma activity. It found its use as a novel
anti-myeloma drug for relapsed and refractory disease in
1999 [8], later yielding impressive overall response rates
of up to 50% when used in combination with dexa-
methasone and up to 65% when combined with corticos-
teroids and cyclophosphamide [9]. Thalidomide, though
effective, was associated with dose-limiting toxicities in-
cluding somnolence, constipation, neuropathy [10], and
increased incidence of venothromboembolism (VTE),
especially when combined with dexamethasone [11].
Hence, a new class of thalidomide derivatives called
IMiDs was developed that, albeit structurally related
(Figure 2, Table 1), had their unique set of anti-inflam-
matory, immunomodulatory, antiproliferative, antiangio-
genic and toxicity profiles [12].
Lenalidomide (CC 5013) was FDA approved for use in
patients with relapsed and/or refractory multipleis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Figure 1 Timeline of advances in myeloma therapy.
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http://www.ehoonline.org/content/1/1/27myeloma after successful clinical trials [13,14]. Lenalido-
mide has a distinct adverse effect profile compared to
thalidomide. Notably, there is an increased risk of grade
3, or greater myelosuppression; however, the rates of
sedation, constipation and neuropathy are all lower than
thalidomide. The risk of VTE varies among studies, and
is dependent on age, concurrent chemotherapy including
dexamethasone, and the use of VTE prophylactic agents.
Importantly, lenalidomide adversely affects adequate
peripheral blood stem cell collection in older patients
with therapy duration greater than 4 months [15,16].
More recently, several investigators have reported an
alarmingly high rate of second malignancies, both mye-
lodysplastic syndrome/acute myeloid leukemia and solid
tumors in newly diagnosed patients with multiple mye-
loma receiving maintenance lenalidomide after autolo-
gous stem cell transplant (Table 2) [17-19]. However,
additional data reported in 2011 Annual Meeting of
American Society of Clinical Oncology did not show anyFigure 2 Molecular stutctures of the IMiD.increase in the rate of second malignancies in transplant
ineligible and relapse or refractory patients undergoing
lenalidomide therapy [20-22]. For example pooled data
from MM-009/010 trials evaluating lenalidomide and
dexamethasone versus dexamethasone/placebo and a
phase II trial evaluating clarithromycin, dexamethasone
and lenalidomide in 72 newly diagnosed multiple mye-
loma patients found similar frequency of second malig-
nancies to background incidence and 2010 SEER data
respectively for non-Multiple Myeloma individuals of
similar age.
Pomalidomide (CC-4047), another derivative of thal-
idomide has shown promising activity in phase I/II trials
in relapsed and refractory multiple myeloma patients,
including patients who have been treated with thalido-
mide, lenalidomide and the 26S proteasome inhibitor
bortezomib (PS-341) [23-26]. Overall pomalidomide
was well tolerated, with thromboembolic events the
major non-hematological dose limiting toxicity, while
Table 1 Pharmacokinetics of the IMiDs
Drug Route of administration Dosage Metabolism/Excretion Half-life Dose adjustments
Thalidomide Oral 50-100 mg Hepatic/Non-renal 4-9 hours None at present
Lenalidomide (CC-5013) Oral 15-25 mg Renal (67% unchanged) 3.1-4.5 hours Adjust for moderate to severe
renal impairment
Pomalidomide (CC-4047) Oral 1-5 mg Renal (67% unchanged) 6.2-7.9 hours None at present
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http://www.ehoonline.org/content/1/1/27neutropenia was the most common dose-limiting tox-
icity noted in initial phase 1 study. Peripheral neur-
opathy was reported by up to 30% of patients; however,
the majority of these were reversible grade 1toxicity
[23,24].
Mechanisms of action
The mechanism of action of the IMiDs is not completely
understood. They are thought to possess anti-prolifera-
tive, anti-angiogenic and immunomodulatory effects
against myeloma cells. Lenalidomide and pomalidomide
exert their anti-myeloma effect dually through direct
down-regulation of key functions of the tumor cell, and
indirectly by modulating interaction of myeloma cells
with their microenvironment. They carry out their direct
effects via modulation of cell adhesion and decreasing
production of key pro-survival cytokines such as TNFal-
pha, IL-6, IL-8, and VEGF that favor tumor cell survival
and proliferation, inhibition of apoptosis, and resistance
to therapy [27].
Both lenalidomide and thalidomide inhibit TNFalpha
production by increasing the degradation of TNFalpha
mRNA and by increasing the activity of alpha-1-acid gly-
coproteins, which have intrinsic anti-TNFalpha activity
[28]. In addition to the anti-angiogenic effect of thalido-
mide, IMiDs have further shown to directly induce
apoptosis by triggering the activation of caspase-8, which
in turn induces myeloma cell death via Fas-mediated
pathways. Dexamethasone also activates caspase-9 path-
way, hence forming the basis of its synergy with the
IMiDs. Lenalidomide also utilizes mitochondrial pathways
to release pro-apoptotic proteins such as cytochrome
c and Smac [29]. Dexamethasone too, has been shown to
release Smac, but not cytochrome c, in myeloma cells,Table 2 Lenalidomide and incidence of second primary malig
Study Patient population
MM-015 Elderly transplant ineligible patients
IFM 2005-02 Newly diagnosed post stem cell transplant
CALGB 100104 Newly diagnosed post stem cell transplanthence providing further molecular basis for the additive
effects of the two drugs, as seen in clinical trials.
IMiDs have shown to down-regulate NF-κB transcrip-
tion activity in vitro, and in effect blunt out the survival
advantage that myeloma cells employ in tumorigenesis.
Dexamethasone has also been shown to down regulate
NF-κB activity, and coupled with lenalidomide nearly
abrogates NF-κB activity in myeloma cells [30]. The net
effect is inhibition of caspase inhibitors, induction of
caspase-8 activity, and promotion of Fas- and TRAIL/
Apo2L- induced apoptosis. IMiDs also block the stimu-
latory effect of insulin like growth-factor-1 on NF-κB ac-
tivity and potentiate the activity of dexamethasone and
proteasome inhibitor therapy.
Furthering their immune modulatory role, the IMiDs
also affects other cellular components in the bone mar-
row. In preclinical studies they have demonstrated acti-
vation of T and NK cells [31-33]. Lenalidomide induces
T-cell proliferation, mainly by co-stimulation of CD28
that in turn leads to increased transcription and produc-
tion of IL-2 and IFN-gamma. It is in fact many times
more potent than its predecessor. As a result of
increased T-cell derived IL-2 and IFN-gamma, and lena-
lidomide and pomalidomide have been shown to aug-
ment CD 56+ NK cell numbers and function [34].
In addition to its diverse immunomodulatory effects,
lenalidomide, although a weaker inhibitor of angiogen-
esis than thalidomide, has a well-documented anti-
angiogenic profile. Instead of directly inhibiting endothe-
lial cell proliferation like its predecessor, lenalidomide in
fact inhibits the secretion of vascular endothelial growth
factor (VEGF) and basic fibroblast growth factor (bFGF),
from both tumor and stromal cells [35]. Lenalidomide





Placebo 302 11 (4%)
Lenolidomide 306 26 (8%)
Placebo 229 6 (2.6%)
Lenolidomide 231 18 (7.8%)
Table 3 Clinical trials-thalidomide (Relapsed/refractory disease)
Author Regimen Type of
clinical trial
No. of pts Best responses
(>PR)
CR, nCR, VGPR PFS/TTP/OS
(months)
Reference
Barlogie et al T Phase II 169 30% CR:2% 2 yr EPS:20% 2 yr OS;48% Blood 2001







Dimpopoulus et al TD Phase II 44 55% >VGPR:30% Median survival 12.6 Annal Oncol 2001
Moehler et al DT-PACE Phase II 50 65% CR:4% PPS:15 1 yr OS:63% Bllod 2001
Terpos E et al VMDT Phase II 62 66% CR:13% VGPR:27% TTP: 9.7 Leukemia 2008
Palumbo et al VMDT Phase II 30% 67% VGPR:43% PPS (1 yr):61% OS
(1 yr):84%
Blood 2007
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http://www.ehoonline.org/content/1/1/27phosphatidylinositol 3-kinase (PI3K)/Akt signaling path-
way, known to be integral in tumor cell survival and
proliferation. Inhibition of this pathway, downstream of
VEGF signaling may explain in part the drug’s anti-
proliferative and anti-angiogenic effects. Lenalidomide
also inhibits VEGF-induced PI3K-Akt pathway signaling,
which is known to regulate adherens junction formation.
A strong inhibitory effect of lenalidomide on hypoxia-
induced endothelial cell formation of cords and hypoxia-
inducible factors (HIF-1) alpha expression, the main me-
diator of hypoxia-mediated effects and a key driver of
angiogenesis and metastasis, has also been found [36].
Pomalidomide and lenalidomide also demonstrated their
potential in epigenetic modulation of p21 WAF-1 ex-
pression, thereby possibly being efficacious in p53
mutated tumors [37].
Recent landmark discovery of cereblon (CRBN), an es-
sential protein to induce thalidomide teratogenicity in
zebrafish and chicken embryos, led to several presenta-
tions at 2011 American society of Hematology (ASH)
meeting demonstrating the critical role of CRBN in anti-
proliferative response to IMiDs [38,39]. Majority of mye-
loma cell lines and patients resistant to IMiDs showed
very low levels of CRBN [40]. In addition, bone marrowTable 4 Clinical trials-thalidomide (Transplant Ineligible)
Author Regimen(s) Type of
clinical
trial
No. of pts Best response
(>PR)
Palumbo et al MPT+T maintenance
vs. MP
Phase III 255 76% vs 47.6%
Facon et al MPT vs MP
vs. HDT/ASCT
Phase III 427 89% vs 37%
vs 83%
Hulin et al MPT vs MP Phase III 229 69% vs 39%
Ludwig et al MPT vs. MP Phase III 231 68% vs 51%
Palumbo et al MPT Phase I/II 53 81%CRBN mRNA expression was also predictive of response




Thalidomide-based chemotherapy combinations are cur-
rently considered front-line regimens in both transplant
eligible and transplant ineligible patients. Initial phase I
data was first described in patients with relapsed and re-
fractory multiple myeloma in 1999 by Singhal et al [9].
A number of subsequent trials utilizing thalidomide
combinations have demonstrated overall response rates
of 46%-67% for relapsed and refractory disease (summar-
ized in Table 3).
Four different phase III trials have evaluated the use of
thalidomide in combination with melphalan/prednisone
(MP) in comparison with MP in transplant in-eligible
patients (Table 4). One of the four trials added thalido-
mide maintenance until relapse [42]. The MPT regimen
demonstrated superior overall responses and complete
responses compared to MP in two of these trials. Al-
though Palumbo et al. also showed improved overall
responses in comparison to MP, but the initial differences CR, nCR, VGPR PFS/TTP/OS
(months)
Reference
CR:15.5% vs. 2.2% OS:45 vs. 47.6
PPS:21.8 vs. 14.5
Blood 2008






















CR:23.8% VGPR:47.6% 1 yr EPS:92% 1 yr OS:100% J Clin Oncol 2007
Table 5 Clinical trials-thalidomide (Transplant Eligible)
Author Regimen(s) Type of
clinical trial
No. of pts Best responses
(>PR)
CR, nCR, VGPR PFS/TTP/OS
(months)
Reference
Rajkumar et al TD vs. D Phase III 470 63% VS. 46% CR+VGPR:44%
vs. 16%
TTP:22.6 vs. 6.4 J Clin Oncol 2008
Lockhorst et al TAD vs. VAD Phase III 402 72% VS. 54% NR NR Haematologica 2008
Cavo et al VTD vs. TD Phase III 187 93% VS. 79% NR NR ASH 2007
Barlogie et al VTD-PACE Phase II 303 99% nCR:83% (2 yr) CR:
56% (2 yr)
EFS:84% (2 yr) OS:
86% (2 yr)
B J Hematol 2007
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questioning the justification of thalidomide maintenance.
One of these trials evaluated the optimal treatment strat-
egy in the elderly MM patients by comparing MP, MPT
and high-dose therapy/autologous stem cell transplant
[43]. This trial showed that MPT had better overall sur-
vival than the other two arms. Based on these trials,
MPT is considered a front-line regimen for transplant
ineligible and elderly MM patients.
Thalidomide-based combinations have also been eval-
uated as induction regimen for transplant-eligible mye-
loma patients (Table 5). It has been observed that
combination of 2 novel agents results in better depth of
response, as seen in combination of thalidomide with
bortezomib and dexamethasone (VTD). The VTD is
often the induction regimen of choice outside of clinical
trials, with overall response rates of 93%. Currently
three-novel drug and four-novel drug regimens are being
evaluated in clinical trials for safety and efficacy. This
strategy certainly holds promise judging by the encour-
aging results of the Total Therapy 3 data (utilizing VTD-
PACE), demonstrating that combining all active anti-
myeloma agents upfront results in overall responses
approaching 100%, and 87% of the complete responders
remain disease free four years from initial therapy [44].
Thalidomide had also been evaluated as maintenance
therapy in several trials. As an example, the recently pub-
lished MRC Myeloma IX trial showed statistically signifi-
cant improvement in progression free survival, 23 vs.
15 months; log-rank P <0.001, in patients receiving low
dose (50 to 100 mg) thalidomide maintenance as com-
pared to placebo. There was no significant difference in
median overall survival P= 0.40. However, a meta-analysisTable 6 Clinical trials-lenalidomide (Relapsed/refractory disea
Author Regimen(s) Type of clinical
trial
No. of pts Best respo
(>PR)
Dimopoulus et al LD Phase III 351 60.2% vs. 2
Weber et al LD Phase IIII 353 61% vs. 19
Palumbo et al MPL-L Phase III 459 77% vs. 49performed by same authors including additional data from
other published studies evaluating thalidomide mainten-
ance showed significant late survival benefit P <0.001 [45].
Lenalidomide
In recent years, lenalidomide has become the lead IMiD in
myeloma clinical investigation due to its superior safety
profile. Two phase II trials have looked at the efficacy of
lenalidomide and dexamethasone in comparison to dexa-
methasone alone, showing superior overall responses,
complete response and overall survival (Table 6). This
combination is also superior to dexamethasone alone in
newly diagnosed patients (Table 7). The efficacy of this
combination was marred by the unacceptably high rates of
venous thromboembolism (26%). An ECOG phase III trial
comparing low-dose dexamethasone to previously utilized
high-dose dexamethasone, found not only reduction in
VTE rates (12%) in the low-dose group, but also an
improved overall survival at the first interim analysis
resulting in suspension of the study [46]. The high-dose
group was subsequently switched to the low dose dexa-
methasone regimen. Niesvizky et al. have shown in a
phase II study that addition of clarithromycin to lenalido-
mide and dexamethasone (BiRD) results in a higher over-
all response rate [47].
With the successful results of combining MP with
thalidomide and then with bortezomib in the elderly
myeloma population, the addition of lenalidomide to
MP was assessed by Palumbo et al. in a phase I/II trial
[48]. The study demonstrated overall response of 81%
with majority of these patients achieving a very good
partial response (VGPR) or better. The results have led
to initiation of an ECOG phase III trial comparing MPTse)
nses CR, nCR, VGPR PFS/TTP/OS
(months)
Reference
4% CR+nCR:15.9% vs. 3.4% TTP:11.7 vs. 4.7
OS:Not reached
vs. 20.7
N Engl J Med 2007
.9% CR:14.4 vs. 0.6% TTP:11.7 vs. 4.7
OS:29.6 vs. 20.2
N. Engl J Med 2007
% CR:18% vs. 5% Not reached ASH 2009 ASCO 2010
Table 7 Clinical trials-lenalidomide (Newly diagnosed)
Author Regimen(s) Type of
clinical
trial
No. of pts Best responses
(>PR)
CR, nCR, VGPR PFS/TTP/OS Reference





Zonder et al LD vs. D Phase III 133 85% vs. 51% NR Not reported ASH 2007
Richardson et al LVD Phase I/II 35 (Phase II) 100% VGPR:69% CR + nCR:54% Not reached at 19.3
months (median)
ASH 2009
Jakubowiak et al LV-PLD-D Phase I/II 26 (Phase II) 96% VGPR:67% CR + nCR:33% Not achieved at 6
months (median)
ASH 2009
Kumar et al LCD vs. VCD
vs. LCVD
Phase II 117 90% vs. 87%
vs. 94%
VGPR:33% vs. 35% vs.
42% CR:12% vs. 6%
vs. 15%
Not reported ASH 2009
Niesvizky et al Clarithromycin
+ LD






Palumbo et al MPL Phase I/II 54 81% VGPR:47.6% CR:23.8% EFS (1 yr):92% OS
(1 yr):100%
JCO 2007
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transplant ineligible myeloma patients.
A number of phase I and II trials are also presently ex-
ploring the combination of lenalidomide with other novel
anti-myeloma agents. Promising results have been observed
with the combination of lenalidomide, dexamethasone and
bortezomib in both newly diagnosed and relapsed/refrac-
tory patients. Updated analysis of phase I/II trial reported
at ASH 2011 showed an overall response rate of 98%, in-
cluding 71% VGPR and 36% CR/nCR for 68 newly diag-
nosed patients, response rate was 100% for 52 patients
treated at maximum planned dose [49]. Similarly impres-
sive results were seen in relapse/refractory patients with
median time to progression of almost 10 months and re-
sponse rate of 78% including 25% complete response [50].
Based on these observations, an ongoing MMRC spon-
sored phase I/II trial evaluating the combination of lenalido-
mide, dexamethasone, bortezomib and liposomal doxorubicin
as first line therapy in newly diagnosed patients showed
greater than 96% partial response with 30% completeTable 8 Clinical trials-pomalidomide
Author Regimen(s) Type of disease/
clinical trial
No. of pts
Lacy M et al Pd Relapsed & refractory
disease/Phase I
60
Schey et al P Relapsed & refractory
disease/Phase I
24
Streetly et al P Relapsed & refractory
disease/Phase I
20
Lacy M et al Pd Lenalinomide & bortezomib
refractory disease/Phase I
34
Richardson P et al Pd Lenalinomide refractory
disease/Phase I
32response in 57 evaluable patients [51]. A Mayo Clinic
lead randomized phase II trial is comparing the combin-
ation of bortezomib, cyclophosphamide, lenalidomide
and dexamethasone with either bortezomib or lenalido-
mide with cyclophosphamide and dexamethasone [52].
Although initial reports of these studies demonstrate un-
precedented overall response rates for the four-drug
combinations. It remains to be seen whether the depth of
response may lead to similar success, and potentially,
cures such as observed in aggressive lymphomas.
Lenalidomide had also shown promising activity as
maintenance therapy after autologous stem cell transplant,
e.g. McCarthy et al. [17] showed median time to progres-
sion of 46 months vs. 27 months (P< 0.001) and Attal
et al. [18] showed median progression-free survival of
41 months, vs. 23 months (P< 0.001) in the lenalidomide
and placebo groups respectively [19,20]. Lenalidomide was
also evaluated in transplant ineligible patients as part of
initial and maintenance therapy. In this trial patients
received melphalan, prednisone, lenalidomide (MPR) asBest responses
(>PR)





PFS:11.6 J Clin Oncol 2009
54% CR:17%VGPR:13%
PR:25%
Not reported J Clin Oncol 2004
50% CR:10% VGPR:30%
PR:10%
PFS:10.5 OS:33 Br J Haematol 2008
50% VGPR:3% PR:29%
MR:18%
Not reported ASCO 2010
52% PR:28% Not reported ASH 2009
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maintenance therapy until relapse or disease progression
or MPR or MP without maintenance therapy. The median
progression-free survival was significantly longer with
MPR-R (31 months) than with MPR (14 months;
P< 0.001) or MP (13 months; P< 0.001).
Pomalidomide
Pomalidomide is the newest IMiD that is undergoing clin-
ical investigation (Table 8). Initial response rates for
relapsed and refractory disease exceed expectation, even
in the patients who have lenalidomide refractory disease
(PR=32%). In an ongoing phase II study, patients who
had failed both lenalidomide and bortezomib were given
pomalidomide and dexamethasone. To date the response
rates with this regimen exceed 50% with an OS of 86%
after 6 months [53]. Treatment benefit with pomalidomide
and low dose dexamethasone was also confirmed by
another Phase II study in patients with multiple myeloma
despite prior use of lenalidomide [54]. In a phase II trial
presented at the 2011 American Society of Hematology
meeting, 46 relapse and refractory patients treated
with pomalidomide, dexamethasone, and clarithromycin
(ClaPD), showed overall response rate of 60% with 27%
showing very good partial remission [55]. Another study
evaluating pomalidomide, cyclophosphamide, prednisone
(PCP) in 41 patients with relapse refractory multiple mye-
loma including lenalidomide refractory patients show 59%
partial response including 2 patients achieving complete
response [56]. More research is needed to establish the
optimal treatment strategy and role of pomalidomide in
patients with relapsed and refractory myeloma.
Conclusion
After over two decades with limited treatment options,
numerous new regimens incorporating novel agents are
now available for both transplant eligible and transplant
ineligible patients with multiple myeloma. While response
rates, adverse reactions and the optimal dosing strategy
vary among the various IMiDs, there is increasing data to
suggest that these novel agents and regimens are altering
the natural history of the disease, improving the quality of
life and longevity of patients with myeloma. Although
teratogenicity is a significant concern and careful monitor-
ing and precautions are required when using these agents,
recent discoveries on the possible mechanism of thalido-
mide teratogenicity will hopefully lead to development of
safer IMiDs [38]. Immunomodulatory drugs are a promis-
ing class of therapy for patients with multiple myeloma,
both as single agents and in combination with conven-
tional chemotherapy.
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